Compare HCA Health Inc (HCA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Xpeng Inc - ADR — how do they compare? HCA Health Inc trades at $414.26 (market cap $89.08B), while Xpeng Inc - ADR trades at $11.76 (market cap $11.15B). The key difference: HCA Health Inc is far larger — about 8× Xpeng Inc - ADR's market cap, and HCA Health Inc pays a 0.76% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| HCA | XPEV | |
|---|---|---|
Market Cap | $89.08B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $545.13 | $28.07 |
52-Week Low | $361.32 | $11.68 |
Enterprise Value | $139.62B | $13.28B |
Dividend Yield | 0.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $413.27, down 0.18% on the day, with strong technical momentum showing a bullish moving average signal. The company reported solid Q2 2026 earnings with EPS of $7.59 beating estimates of $7.56, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $75.60 billion, while maintaining healthy profit margins of 8.77%. Recent management appointments and ongoing legal investigations create mixed sentiment around the stock.
HCA presents a compelling value opportunity with attractive valuation multiples (P/E 13.8, EV/EBITDA 8.8) and strong analyst support (63% buy ratings, $449.93 price target). However, investors face risks from multiple ongoing legal investigations, high debt levels (debt-to-asset ratio 80.9% in 2025), and margin pressure from rising operational costs. The stock offers 8.9% upside to consensus target but requires monitoring of legal developments and expense management.
XPeng (XPEV) trades at $11.76, down 2.04% today, amid a bearish technical signal. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with profitability metrics like ROE at -7.64% remaining weak. Recent news highlights expansion into robotics and overseas markets, including a new SUV launch in Munich, while July 2026 deliveries increased 4% year-over-year to 38,027 vehicles.
The stock offers potential upside to the $17.00 analyst consensus target but faces risks from persistent losses, intense EV competition, and macroeconomic pressures. Investor sentiment is mixed, with 64.7% of analysts rating it a buy, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
